Navigation Links
GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in 'Sirtuin' Research and Development
Date:4/22/2008

.com" target="_new">http://www.gsk.com.

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction by activation of sirtuins, a recently discovered class of enzymes that the Company believes control the ageing process. The company's headquarters are in Cambridge, Massachusetts.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Action of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk factors' in the 'Business Review' in the company's Annual Report 2007.

Important Additional Information Will Be Filed with the Securities Exchange Commission (SEC)

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Sirtris Pharmaceuticals, Inc. The tender offer for shares of Sirtris's stock described in this press release has not yet been commenced.

At the time the tender offer is commenced, a subsidiary of GSK intends to file with the SEC and mail to Sirtris's stockholders a Tender Offer Statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal and other related documents, and Sirtris intends to file with the SEC and mail to its stockholders a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 in connection with the transaction. Th
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
10. Vaccinex Antibody Licensed to GlaxoSmithKline
11. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/27/2014)... Varian Medical Systems today broke ground ... Lake City manufacturing facility and allow for the consolidation ... create 1,000 new full time jobs in the state ... home to hardworking people with immense engineering and technical ... success in the manufacturing of our state-of-the-art X-ray technology,” ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 /PRNewswire/ ... research report is available in its catalogue: ... 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials are materials that are readily decomposed ... differs from conventional non-degradable packaging in terms ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... p.m. EDT -, VALENCIA, Calif., Aug. 11 ... for the second,quarter ended June 30, 2008., For ... $80.9,million, compared to $75.4 million for the second quarter ... and development,(R&D) expenses which totaled $67.6 million for this ...
... Aug. 11 Immtech Pharmaceuticals,Inc. (Amex: IMM ) ... 2008., For the three months ended June 30, ... three months ended June 30, 2007. The increase,was primarily ... from operations for the three months ended June 30, ...
... Informed Medical Communications,(IMC), a leading provider of ... position today on recent revisions,to the PhRMA Code. ... Code," noted Dr. Jaime Nguyen, Medical Director/Compliance Officer,for ... continually monitored,the compliance trends so that our services ...
Cached Biology Technology:MannKind Corporation Reports Second Quarter Financial Results 2MannKind Corporation Reports Second Quarter Financial Results 3MannKind Corporation Reports Second Quarter Financial Results 4MannKind Corporation Reports Second Quarter Financial Results 5MannKind Corporation Reports Second Quarter Financial Results 6Immtech Reports Fiscal First Quarter 2009 Results 2Immtech Reports Fiscal First Quarter 2009 Results 3Informed Medical Communications Highlights Opportunity in Revised PhRMA Code 2
(Date:8/28/2014)... Researchers at the University of Minnesota have developed an ... be used for muscle regeneration research as well as ... , The research is published in the current edition ... is no treatment for FSHD, which is thought by ... dystrophy. FSHD is an unusual genetic disorder because, unlike ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
(Date:8/28/2014)... More than 25 million kilometres of new roads will ... will slice into Earth,s last wildernesses, where they bring ... , Now, an ambitious study has created a ... to try to balance the competing demands of development ... an ,environmental-values, layer that estimates that natural importance of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... This press release is available in Spanish ... losses to the atmosphere through volatilization also rise. ... (USDA) scientists found that herbicide volatilization consistently resulted in ... Agricultural Research Service (ARS) soil scientist Timothy ...
... it has not stopped her from working. Thanks in part ... her 13th year as an account executive for a firm ... are not as fortunate. In the United States, the ... as systemic sclerosis, is two to three times that of ...
... of scientists has produced a new map of the ... an ultra-nutritious potato that could help feed the world,s ... genome of the potato, the consortium has, for the ... Resulting insights into the growth and development of potatoes ...
Cached Biology News:Researchers study pesticide pathways into the atmosphere 2Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
Request Info...
... Nebulizers are available in two product models - ... two models is that the 6000AT+ includes a ... drier aerosol for improved detection limits and reduced ... a range of elements by 10-40 times. Note ...
Biology Products: